Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Vasilis Fragoulakis, Elli Vitsou, Ana Cristina Hernandez & Nikolaos Maniadakis. (2015) Economic evaluation of anti-TNF agents for patients with rheumatoid arthritis in Greece. ClinicoEconomics and Outcomes Research 7, pages 85-93.
Read now
Read now
Erika Catay, Cecilia Castel del Cid, Lorena Narváez, Edson J Velozo, Javier E Rosa, Luis J Catoggio & Enrique R Soriano. (2012) Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era. ClinicoEconomics and Outcomes Research 4, pages 219-225.
Read now
Read now
Andrew Alldred. (2001) Etanercept in rheumatoid arthritis. Expert Opinion on Pharmacotherapy 2:7, pages 1137-1148.
Read now
Read now
Ernest HS Choy. (1998) New prospects for the treatment of rheumatoid arthritis. Expert Opinion on Investigational Drugs 7:7, pages 1087-1097.
Read now
Read now
Articles from other publishers (19)
Elena Nikiphorou, Charlotte Davies, Miranda Mugford, Nicola Cooper, Alan Brooksby, Diane K. Bunn, Adam Young, Suzanne M.M. Verstappen, Deborah P.M. Symmons & Alex J. MacGregor. (2015) Direct Health Costs of Inflammatory Polyarthritis 10 Years after Disease Onset: Results from the Norfolk Arthritis Register. The Journal of Rheumatology 42:5, pages 794-798.
Crossref
Crossref
Denis Wakefield, Nick Di Girolamo, Stephan Thurau, Gerhild Wildner & Peter McCluskey. (2013) Scleritis: Immunopathogenesis and molecular basis for therapy. Progress in Retinal and Eye Research 35, pages 44-62.
Crossref
Crossref
Christoph Ackermann & Arthur Kavanaugh. (2008) Economic Burden of Psoriatic Arthritis. PharmacoEconomics 26:2, pages 121-129.
Crossref
Crossref
Yolanda Bravo Vergel & David Torgerson. 2008. Clinical Trials in Rheumatoid Arthritis and Osteoarthritis. Clinical Trials in Rheumatoid Arthritis and Osteoarthritis
289
307
.
Rafael Ariza-Ariza & Blanca Hernández-Cruz. (2007) Artritis reumatoide: ¿cuán cara es?. Seminarios de la Fundación Española de Reumatología 8:1, pages 15-27.
Crossref
Crossref
Saralynn Allaire, Frederick Wolfe, Jingbo Niu, Nancy Baker, Kaleb Michaud & Michael Lavalley. (2006) Extent of occupational hand use among persons with rheumatoid arthritis. Arthritis & Rheumatism 55:2, pages 294-299.
Crossref
Crossref
R. Garca de Vicua Pinedo & A. Ortiz Garca. (2005) Artritis reumatoide (I). Etiopatogenia. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9:28, pages 1805-1814.
Crossref
Crossref
Hubertus Rosery, Rito Bergemann & Stefanie Maxion-Bergemann. (2005) International Variation in Resource Utilisation and Treatment Costs for Rheumatoid Arthritis. PharmacoEconomics 23:3, pages 243-257.
Crossref
Crossref
Nick J Bansback, Dean A Regier, Roberta Ara, Alan Brennan, Kamran Shojania, John M Esdaile, Aslam H Anis & Carlo A Marra. (2005) An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis. Drugs 65:4, pages 473-496.
Crossref
Crossref
Anne-Christine Rat & Marie-Christophe Boissier. (2004) Polyarthrite rhumatoïde : coûts directs et indirects. Revue du Rhumatisme 71:12, pages 1122-1129.
Crossref
Crossref
Anne-Christine Rat & Marie-Christophe Boissier. (2004) Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine 71:6, pages 518-524.
Crossref
Crossref
Diane Lacaille, Samuel Sheps, John J. Spinelli, Andrew Chalmers & John M. Esdaile. (2004) Identification of modifiable work‐related factors that influence the risk of work disability in rheumatoid arthritis. Arthritis Care & Research 51:5, pages 843-852.
Crossref
Crossref
Tore K. Kvien. (2012) Epidemiology and burden of illness of rheumatoid arthritis. PharmacoEconomics 22:S1, pages 1-12.
Crossref
Crossref
Edward Yelin, Miriam G. Cisternas, David J. Pasta, Laura Trupin, Louise Murphy & Charles G. Helmick. (2004) Medical care expenditures and earnings losses of persons with arthritis and other rheumatic conditions in the United States in 1997: Total and incremental estimates. Arthritis & Rheumatism 50:7, pages 2317-2326.
Crossref
Crossref
John B Wong, Gurkirpal Singh & Arthur Kavanaugh. (2002) Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. The American Journal of Medicine 113:5, pages 400-408.
Crossref
Crossref
Edward Yelin, Aldona Herrndorf, Laura Trupin & Dean Sonneborn. (2001) A national study of medical care expenditures for musculoskeletal conditions: The impact of health insurance and managed care. Arthritis & Rheumatism 44:5, pages 1160-1169.
Crossref
Crossref
Elke Hunsche, Jeremy V.M. Chancellor & Nick Bruce. (2001) The Burden of Arthritis and Nonsteroidal Anti-Inflammatory Treatment. PharmacoEconomics 19:Supplement 1, pages 1-15.
Crossref
Crossref
N. J. Cooper. (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:1, pages 28-33.
Crossref
Crossref
Ernest H. S. Choy, Gabrielle H. Kingsley & Gabriel S. Panayi. (1998) Anti-CD4 monoclonal antibodies in rheumatoid arthritis. Springer Seminars in Immunopathology 20:1-2, pages 261-273.
Crossref
Crossref